WuXi Biologics and Medigene Enter into a Research Collaboration for Off-the-Shelf TCR-Guided T Cell Engagers
WuXi Biologics (WXXWY) and Medigene AG have entered into a three-year strategic partnership to design and co-research T cell receptor (TCR)-guided T Cell Engagers (TCR-TCEs) for treating difficult-to-treat tumors. The collaboration combines Medigene's 3S (sensitive, specific and safe) TCR generation and characterization capabilities with WuXi Biologics' unique anti-CD3 mAb, TCE platform, and WuXiBody™ bispecific antibody platform. This partnership aims to enhance WuXi Biologics' research service capabilities and apply Medigene's TCRs to new modalities, potentially creating additional value for patients and shareholders beyond TCR-T therapies.
WuXi Biologics (WXXWY) e Medigene AG hanno avviato una collaborazione strategica triennale per progettare e co-ricercare engager di cellule T guidati da recettori T (TCR) per il trattamento di tumori difficili da trattare. La collaborazione unisce le capacità di Medigene nella generazione TCR 3S (sensibile, specifico e sicuro) e nella caratterizzazione con la piattaforma TCE unica di WuXi Biologics, l’anticorpo monoclonale anti-CD3 e la piattaforma bispecifica WuXiBody™. Questo accordo mira a potenziare le capacità di servizio di ricerca di WuXi Biologics e ad applicare i TCR di Medigene a nuove modalità, creando potenzialmente ulteriore valore per pazienti e azionisti oltre alle terapie TCR-T.
WuXi Biologics (WXXWY) y Medigene AG han establecido una asociación estratégica de tres años para diseñar e investigar conjuntamente engagers de células T guiados por receptores T (TCR) para el tratamiento de tumores difíciles de tratar. La colaboración combina las capacidades de Medigene en la generación de TCR 3S (sensible, específico y seguro) y caracterización con la plataforma única de TCE de WuXi Biologics, el anticuerpo monoclonal anti-CD3 y la plataforma de anticuerpos bispecíficos WuXiBody™. Esta asociación tiene como objetivo mejorar las capacidades de servicio de investigación de WuXi Biologics y aplicar los TCR de Medigene a nuevas modalidades, potencialmente creando valor adicional para los pacientes y accionistas más allá de las terapias TCR-T.
WuXi Biologics (WXXWY)와 Medigene AG는 3년 전략적 파트너십을 체결하여 치료가 어려운 종양을 위한 T 세포 수용체(TCR) 유도 T세포 이어잡이(TCR-TCE)를 설계하고 공동 연구합니다. 이 협력은 Medigene의 3S(민감하고, 특정하며, 안전한) TCR 생성 및 특성화 능력과 WuXi Biologics의 독창적인 anti-CD3 단클론 항체, TCE 플랫폼 및 WuXiBody™ 이중 특이성 항체 플랫폼을 결합합니다. 이 파트너십은 WuXi Biologics의 연구 서비스 능력을 향상시키고 Medigene의 TCR을 새로운 양식에 적용하여 TCR-T 요법을 넘어 환자와 주주에게 추가 가치를 창출하는 것을 목표로 합니다.
WuXi Biologics (WXXWY) et Medigene AG ont conclu un partenariat stratégique de trois ans pour concevoir et co-rechercher des engagers de cellules T guidés par des récepteurs T (TCR) pour le traitement des tumeurs difficiles à traiter. La collaboration combine les capacités de Medigene en matière de génération de TCR 3S (sensible, spécifique et sûr) et de caractérisation avec la plateforme unique de TCE de WuXi Biologics, l'anticorps monoclonal anti-CD3 et la plateforme d'anticorps bispécifiques WuXiBody™. Ce partenariat vise à améliorer les capacités de services de recherche de WuXi Biologics et à appliquer les TCR de Medigene à de nouvelles modalités, créant potentiellement une valeur supplémentaire pour les patients et les actionnaires au-delà des thérapies TCR-T.
WuXi Biologics (WXXWY) und Medigene AG haben eine drei-jährige strategische Partnerschaft gegründet, um T-Zell-Rezeptor (TCR)-gesteuerte T-Zell-Engager (TCR-TCE) zur Behandlung von schwer behandelbaren Tumoren zu entwerfen und gemeinsam zu erforschen. Die Zusammenarbeit vereint die 3S (sensibel, spezifisch und sicher) TCR-Generierung und -Charakterisierungsmöglichkeiten von Medigene mit der einzigartigen anti-CD3 mAb, TCE-Plattform und WuXiBody™ bispezifischen Antikörperplattform von WuXi Biologics. Ziel dieser Partnerschaft ist es, die Forschungsdienstleistungen von WuXi Biologics zu verbessern und die TCRs von Medigene auf neue Modalitäten anzuwenden, was potenziell zusätzlichen Wert für Patienten und Aktionäre über TCR-T-Therapien hinaus schaffen könnte.
- Strategic partnership to develop TCR-guided T Cell Engagers for difficult-to-treat tumors
- Combination of Medigene's TCR expertise with WuXi Biologics' advanced platforms
- Potential to enhance WuXi Biologics' research service capabilities
- Opportunity for Medigene to expand its TCR applications beyond cellular therapies
- None.
- Partnership leverages Medigene's leadership for T cell receptor (TCR) generation and characterization and WuXi Biologics' unique anti-CD3 mAb, its T cell engager (TCE) platform and proprietary bispecific antibody platform WuXiBody™
- Collaboration is a three-year and potentially multi-TCR program partnership
Dr. Chris Chen, CEO of WuXi Biologics, commented, "We are excited to partner with Medigene, a leader in TCR generation and characterization. This collaboration will further enhance our research service capabilities in our CRDMO business model and underscore our commitment to enabling global partners to speed up their novel therapy discovery and development with our leading technologies and reliable services. I believe the partnership will be ultimately translated into better treatments for cancer patients worldwide."
"We are confident that Medigene's known capabilities in generating potential best-in-class 3S TCRs for TCR-T cell therapies can also be applied to non-cellular modalities," said Selwyn Ho, CEO of Medigene. "As such, we are delighted to be able to partner with WuXi Biologics with their validated anti-CD3 mAb, and its industry leading TCE platform and WuXiBody™ to support our strategy to apply Medigene's TCRs into new modalities, such as TCR-TCEs for use in patients where additional value can be created beyond TCR-T therapies, for patients and our shareholders."
WuXiBodyTM is a leading proprietary bispecific antibody platform developed by WuXi Biologics. It can effectively break through the discovery and CMC barriers for the development of many bispecific antibodies with high expression yield, high stability, good solubility, and easy purification to homogeneity, expedite the process by 6-18 months and significantly reduce manufacturing costs, limitations still faced by many other current bispecific platforms. WuXiBodyTM platform enables almost any mAb sequence pairs to be assembled into bispecific constructs, which are expected to have low immunogenicity risk and longer in vivo half-life. WuXiBodyTM platform also has a unique structural flexibility, which makes it convenient to build various formats with different combinations of valencies (1+1, 1+2, 2+2) to meet the requirements of different target biology.
About WuXi Biologics
WuXi Biologics (2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to be an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com.
About Medigene AG
Medigene AG (FSE: MDG1) is an immuno-oncology platform company dedicated to developing T cell receptor (TCR)-guided therapies to effectively eliminate cancer. Its End-to-End Platform generates optimal 3S (sensitive, specific and safe) T cell receptors with unique and distinctive attributes that are utilized in multiple therapeutic modalities such as T cell receptor engineered T cell (TCR-T) therapies, TCR-guided T cell engager therapies and TCR-natural killer cell therapies for both its in-house product pipeline and partnering.
Medigene's lead TCR-T program MDG1015 is a potential best-in-class, TCR-T therapy to treat multiple solid tumor indications. The End-to-End Platform technologies enable armoring and enhancing of these T cells to overcome the immunosuppressive tumor microenvironment (TME) and ensure the T cell drug product composition maximizes safety, efficacy and durability of response. Medigene's MDG1015 is on track for IND filing in Q3 2024 and CTA filing in Q4 2024. For more information, please visit www.medigene.com
View original content:https://www.prnewswire.com/news-releases/wuxi-biologics-and-medigene-enter-into-a-research-collaboration-for-off-the-shelf-tcr-guided-t-cell-engagers-302217372.html
SOURCE WuXi Biologics
FAQ
What is the duration of the partnership between WuXi Biologics and Medigene?
What is the focus of the WuXi Biologics and Medigene collaboration?
What technologies are WuXi Biologics contributing to the partnership?
What expertise is Medigene bringing to the collaboration with WuXi Biologics?
